A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Pfeifer, Gerd, Ph.D. Bookmark and Share

Laboratory of Gerd Pfeifer, Ph.D.

The laboratory studies biological mechanisms involved in human cancer. Our goal is to determine the molecular mechanisms that are involved in formation of genetic changes (gene mutations) and epigenetic changes (DNA methylation and histone modifications) in the human genome.

The main research topic in the laboratory is epigenetic gene regulation in development and disease. Many genes are silenced by DNA methylation and by other repressive epigenetic mechanisms in human tumors. Methylated genes hold great promise not only as functionally relevant silenced genes involved in tumorigenesis but also as biomarkers for cancer diagnosis. We developed a sensitive method for analysis of DNA methylation on a genome-wide scale, the methylated-CpG island recovery assay (MIRA). MIRA is used to identify new commonly methylated genes in human tumors. Homeobox genes, known to be involved in developmental processes and tissue specification, are very frequently methylated in lung cancers and many other human tumors. We found that the mechanisms of cancer-specific DNA hypermethylation often involves targeting of specific DNA sequences, in particular homeobox genes, by the Polycomb repression complex and this pathway is already prevalent in inflamed tissue predisposing epithelial cells to malignant transformation. Using bioinformatics approaches, we are trying to uncover mechanisms dependent on DNA sequence features and DNA binding proteins that determine the specificity of DNA methylation changes in human cancers. We are also investigating changes in the epigenome in response to exposure of cells to environmental carcinogens including ultraviolet and ionizing radiation. Another project will attempt to establish a link between tissue aging and malignant transformation based on common changes in epigenetic regulation that underlie these processes. Very recently, previously unrecognized DNA bases, including 5-hydroxymethylcytosine, 5-formyl-, and 5-carboxy-cytosine, have been detected in certain mammalian tissues and cell types. We developed methodology to determine the sequence location of 5-hydroxymethylcytosine in mammalian DNA and found that it is targeted to promoters and gene bodies. In collaboration with Piroska Szabó’s lab, we showed that 5-methylcytosine is oxidized to 5-hydroxymethylcytosine selectively in the paternal genome of fertilized oocytes as part of a transgenerational epigenetic reprogramming mechanism. We showed that 5-hydroxymethylcytosine is strongly depleted in human cancers and could therefore be used as a biomarker for malignancy. Future work will focus on the distribution patterns and on the enzymology of 5-hydroxymethylcytosine formation and removal and its biological function in normal and malignant tissues.
 
For more information on Dr. Pfeifer, please click here.

5-hydroxymethylcytosine

 
5-methylcytosine (5mC) can be oxidized enzymatically by the TET family of proteins to form 5-hydroxymethylcytosine (5hmC). This process occurs genome-wide in the sperm-derived paternal genome shortly after fertilization (Iqbal et al., 2011). One popular model proposes that 5hmC is a transient intermediate in DNA demethylation. However, this issue is still unresolved and needs to be investigated further. We found that 5hmC is strongly depleted in many types of human cancer and could be developed as a biomarker for malignant disease (Jin et al., 2011). One of our hypotheses is that defects in 5mC oxidation are responsible for altered DNA methylation patterns in tumors (and possibly other diseases). We have established and used methodology for precise quantification and genome-wide mapping of 5mC and 5hmC. Our goal is to determine the levels and the genomic distribution of 5hmC in normal human tissues and in malignant tumors. We will focus on several tumor types, including solid tumors and hematological malignancies, which are often characterized by mutations in one of the TET genes, TET2, a methylcytosine oxidase. We work on basic mechanistic studies of TET and TET-associated proteins (for example, CXXC domain containing proteins), their aberrations in cancer and on their functional roles in control of CpG island methylation and cell differentiation.
 
Iqbal, K., Jin, S.-G., Pfeifer, G.P., and Szabó, P.E. (2011) Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine  Proc. Natl. Acad. Sci. USA 108, 3642-3647.
 
Jin, S.-G., Jiang, Y., Qiu, R., Rauch, T.A., Wang, Y., Schackert, G., Krex, D., Lu, Q., and Pfeifer, G.P. (2011) 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations, Cancer Res. 71, 7360-7365.
 
Hahn, M.A., Qiu, R., Wu, X., Li, A.X., Wang, J., Zhang, H., Jui, J., Jin, S.G., Jiang, Y., Pfeifer, G.P.,* and Lu, Q.* (2013) Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis, Cell Reports 3, 291-300.
 
Pfeifer, G.P., Kadam, S., and Jin, S.-G. (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer, Epigenetics Chromatin 6(1):10.
 

 
 

Aging and the unstable epigenome

Various hypotheses have been put forward to explain the aging process at both the cellular and organismal level. We investigate if and how alterations of the epigenome contribute to the aging process. We analyze several epigenetic marks including DNA CpG methylation and chromatin modifications in cells and tissues that undergo aging in vitro and in vivo. This work includes an in-depth analysis of the epigenome at the level of histone modifications, DNA methylation and gene expression during the time course of human in vivo aging and in premature aging syndromes. The data will allow an estimation of the extent and specificity of epigenetic changes that occur during aging.
 
 
 
 
 

DNA methylation and cancer

5-methylcytosine (5mC) is a modified DNA base that plays an important role in gene regulation. One major focus of the laboratory is to study DNA methylation patterns in normal and cancer tissues (Rauch et al., 2008; Hahn et al., 2008; Rauch et al., 2009; Wu et al., 2010; Kalari, Jung et al., 2013). Despite of thousands of reports in the literature describing hypermethylation of specific genes in almost every type of human cancer, the mechanisms and biological significance of CpG island hypermethylation in tumors have remained obscure. Our work focuses on studies that will investigate the molecular pathways leading to DNA methylation changes in tumors. Our general hypothesis is that CpG island hypermethylation is driven by specific mechanisms, either by exogenous or endogenous carcinogenic agents, by inflammation, by oncogene activation leading to epigenetic changes, and/or by targeted mechanisms involving the Polycomb repression complex.
 
Rauch, T.A., Zhong,, X., Wu,, X., Wang,, M., Kernstine,, K.H., Wang,, Z., Riggs,, A.D., and Pfeifer, G.P. (2008) High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer, Proc. Natl. Acad. Sci. USA 105, 252-257.
 
Hahn, M.A., Hahn, T., Lee, D.-H., Esworthy, R.S., Kim, B.-W., Riggs, A.D., Chu, F.F., and Pfeifer, G.P. (2008) Methylation of Polycomb target genes in intestinal cancer is mediated by inflammation, Cancer Res. 68, 10280-10289.
 
Rauch, T.A., Wu, X., Zhong, X., Riggs, A.D., and Pfeifer, G.P. (2009) A human B cell methylome at 100 bp resolution, Proc. Natl. Acad. Sci. USA 106, 671-678.
 
Wu, X., Rauch, T.A., Zhong, X., Bennett, W.P., Latif, F., Krex, D., and Pfeifer, G.P. (2010) CpG island hypermethylation in human astrocytomas, Cancer Res. 70, 2718-2727.
 
Kalari, S., Jung, M., Kernstine, K.H., Takahashi, T., and Pfeifer, G.P. (2013) The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells, Oncogene 32, 3559-3568.
 
 

Mammalian neurogenesis

In collaboration with Dr. Qiang Lu, City of Hope, we are investigating changes in DNA cytosine modification and histone modifications in the developing mouse brain. The focus is on how these epigenetic events orchestrate gene expression patterns during neurogenesis (Hahn et al., 2013).
 
Hahn, M.A., Qiu, R., Wu, X., Li, A.X., Wang, J., Zhang, H., Jui, J., Jin, S.G., Jiang, Y., Pfeifer, G.P.,* and Lu, Q.* (2013) Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis, Cell Reports 3, 291-300.
 
 

RASSF1 and the Hippo pathway

The biological significance of aberrant methylation in cancer (“driver” versus “passenger” methylation) is unclear (Kalari et al., 2010). Earlier, we identified and characterized the gene RASSF1A (Dammann et al., 2000). This gene undergoes methylation silencing in almost every type of human tumor (~1000 publications in PubMed). In the face of increasing numbers of cancer genome sequencing studies identifying mutations in critical genes, researchers are loosing sight of the breadth and significance of cancer-associated promoter hypermethylation. The RASSF1A pathway is a prime example highlighting the importance of epigenetic silencing events in tumors in the absence of frequent mutation of a gene. We identified RASSF1A as an upstream regulator of the Hippo tumor suppressor pathway (Guo et al., 2007). Interestingly, the one component of the Hippo pathway most frequently affected in human cancer is RASSF1A, which is silenced by promoter methylation in over 90% of human liver tumors, for example. Therefore, this promoter methylation is of high significance and we continue to study the biochemical function of RASSF1A and its related family members in the mammalian Hippo pathway and other tumor-relevant processes.
 
Dammann, R., Li, C., Yoon, J.-H., Chin, P.L., Bates, S., and Pfeifer, G.P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nature Genet. 25, 315-319.
 
Guo, C., Tommasi, S., Liu, L., Yee, J.-K., Dammann, R., and Pfeifer, G.P. (2007) The RASSF1A tumor suppressor protein is a component of a mammalian complex analogous to the Drosophila Hippo/Salvador/Lats tumor suppressor network, Curr. Biol. 17, 700-705.
 
Kalari, S., and Pfeifer, G.P. (2010) Identification of driver and passenger DNA methylation in cancer by epigenomic analysis, Adv. Genet. 70, 277-308.
 
Pfeifer, G.P., Dammann, R., and Tommasi, S. (2010) RASSF proteins, Curr. Biol. 20, R344-R345.
 

 
 

UV damage and repair

Exposure to ultraviolet (UV) causes melanoma and non-melanoma skin cancer in humans and UV-specific mutation patterns can be found in tumor genomes (Pfeifer and Hainaut, 2011). This work is an ongoing project supporting studies on UV-induced DNA damage, repair and mutagenesis. Part of the current work is aimed at investigating mechanisms of epigenetic changes induced by different types of UV radiation (Lahtz et al., 2013). One main goal is to obtain high-resolution DNA damage maps of UV-induced cyclobutane pyrimidine dimers (CPDs), the main DNA lesion induced by UVB radiation. We are currently developing methodology for base-resolution mapping of CPDs thus allowing a precise assessment of genomic UV damage and its relationship to features of DNA sequence and chromatin. Another goal is to study epigenetic changes in melanoma and relate them to genetic changes in the same tumors.
 
Pfeifer, G.P. and Hainaut, P., (2011) Next generation sequencing: emerging lessons on the origins of human cancer, Curr. Opin. Oncol. 23, 62–68.
 
Lahtz, C., Kim, S.I., Bates, S.E., Li, A.X., Wu, X., and Pfeifer, G.P. (2013) UVB irradiation does not directly induce detectable changes of DNA methylation in human keratinocytes, F1000Research, v1, online Feb 13, 2013. http://f1000r.es/np.

 
 

Gerd Pfeifer, Ph.D. Lab Members

 
 

Pfeifer, Gerd, Ph.D.

Laboratory of Gerd Pfeifer, Ph.D.

The laboratory studies biological mechanisms involved in human cancer. Our goal is to determine the molecular mechanisms that are involved in formation of genetic changes (gene mutations) and epigenetic changes (DNA methylation and histone modifications) in the human genome.

The main research topic in the laboratory is epigenetic gene regulation in development and disease. Many genes are silenced by DNA methylation and by other repressive epigenetic mechanisms in human tumors. Methylated genes hold great promise not only as functionally relevant silenced genes involved in tumorigenesis but also as biomarkers for cancer diagnosis. We developed a sensitive method for analysis of DNA methylation on a genome-wide scale, the methylated-CpG island recovery assay (MIRA). MIRA is used to identify new commonly methylated genes in human tumors. Homeobox genes, known to be involved in developmental processes and tissue specification, are very frequently methylated in lung cancers and many other human tumors. We found that the mechanisms of cancer-specific DNA hypermethylation often involves targeting of specific DNA sequences, in particular homeobox genes, by the Polycomb repression complex and this pathway is already prevalent in inflamed tissue predisposing epithelial cells to malignant transformation. Using bioinformatics approaches, we are trying to uncover mechanisms dependent on DNA sequence features and DNA binding proteins that determine the specificity of DNA methylation changes in human cancers. We are also investigating changes in the epigenome in response to exposure of cells to environmental carcinogens including ultraviolet and ionizing radiation. Another project will attempt to establish a link between tissue aging and malignant transformation based on common changes in epigenetic regulation that underlie these processes. Very recently, previously unrecognized DNA bases, including 5-hydroxymethylcytosine, 5-formyl-, and 5-carboxy-cytosine, have been detected in certain mammalian tissues and cell types. We developed methodology to determine the sequence location of 5-hydroxymethylcytosine in mammalian DNA and found that it is targeted to promoters and gene bodies. In collaboration with Piroska Szabó’s lab, we showed that 5-methylcytosine is oxidized to 5-hydroxymethylcytosine selectively in the paternal genome of fertilized oocytes as part of a transgenerational epigenetic reprogramming mechanism. We showed that 5-hydroxymethylcytosine is strongly depleted in human cancers and could therefore be used as a biomarker for malignancy. Future work will focus on the distribution patterns and on the enzymology of 5-hydroxymethylcytosine formation and removal and its biological function in normal and malignant tissues.
 
For more information on Dr. Pfeifer, please click here.

5-hydroxymethylcytosine

5-hydroxymethylcytosine

 
5-methylcytosine (5mC) can be oxidized enzymatically by the TET family of proteins to form 5-hydroxymethylcytosine (5hmC). This process occurs genome-wide in the sperm-derived paternal genome shortly after fertilization (Iqbal et al., 2011). One popular model proposes that 5hmC is a transient intermediate in DNA demethylation. However, this issue is still unresolved and needs to be investigated further. We found that 5hmC is strongly depleted in many types of human cancer and could be developed as a biomarker for malignant disease (Jin et al., 2011). One of our hypotheses is that defects in 5mC oxidation are responsible for altered DNA methylation patterns in tumors (and possibly other diseases). We have established and used methodology for precise quantification and genome-wide mapping of 5mC and 5hmC. Our goal is to determine the levels and the genomic distribution of 5hmC in normal human tissues and in malignant tumors. We will focus on several tumor types, including solid tumors and hematological malignancies, which are often characterized by mutations in one of the TET genes, TET2, a methylcytosine oxidase. We work on basic mechanistic studies of TET and TET-associated proteins (for example, CXXC domain containing proteins), their aberrations in cancer and on their functional roles in control of CpG island methylation and cell differentiation.
 
Iqbal, K., Jin, S.-G., Pfeifer, G.P., and Szabó, P.E. (2011) Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine  Proc. Natl. Acad. Sci. USA 108, 3642-3647.
 
Jin, S.-G., Jiang, Y., Qiu, R., Rauch, T.A., Wang, Y., Schackert, G., Krex, D., Lu, Q., and Pfeifer, G.P. (2011) 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations, Cancer Res. 71, 7360-7365.
 
Hahn, M.A., Qiu, R., Wu, X., Li, A.X., Wang, J., Zhang, H., Jui, J., Jin, S.G., Jiang, Y., Pfeifer, G.P.,* and Lu, Q.* (2013) Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis, Cell Reports 3, 291-300.
 
Pfeifer, G.P., Kadam, S., and Jin, S.-G. (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer, Epigenetics Chromatin 6(1):10.
 

 
 

Aging and the unstable epigenome

Aging and the unstable epigenome

Various hypotheses have been put forward to explain the aging process at both the cellular and organismal level. We investigate if and how alterations of the epigenome contribute to the aging process. We analyze several epigenetic marks including DNA CpG methylation and chromatin modifications in cells and tissues that undergo aging in vitro and in vivo. This work includes an in-depth analysis of the epigenome at the level of histone modifications, DNA methylation and gene expression during the time course of human in vivo aging and in premature aging syndromes. The data will allow an estimation of the extent and specificity of epigenetic changes that occur during aging.
 
 
 
 
 

DNA methylation and cancer

DNA methylation and cancer

5-methylcytosine (5mC) is a modified DNA base that plays an important role in gene regulation. One major focus of the laboratory is to study DNA methylation patterns in normal and cancer tissues (Rauch et al., 2008; Hahn et al., 2008; Rauch et al., 2009; Wu et al., 2010; Kalari, Jung et al., 2013). Despite of thousands of reports in the literature describing hypermethylation of specific genes in almost every type of human cancer, the mechanisms and biological significance of CpG island hypermethylation in tumors have remained obscure. Our work focuses on studies that will investigate the molecular pathways leading to DNA methylation changes in tumors. Our general hypothesis is that CpG island hypermethylation is driven by specific mechanisms, either by exogenous or endogenous carcinogenic agents, by inflammation, by oncogene activation leading to epigenetic changes, and/or by targeted mechanisms involving the Polycomb repression complex.
 
Rauch, T.A., Zhong,, X., Wu,, X., Wang,, M., Kernstine,, K.H., Wang,, Z., Riggs,, A.D., and Pfeifer, G.P. (2008) High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer, Proc. Natl. Acad. Sci. USA 105, 252-257.
 
Hahn, M.A., Hahn, T., Lee, D.-H., Esworthy, R.S., Kim, B.-W., Riggs, A.D., Chu, F.F., and Pfeifer, G.P. (2008) Methylation of Polycomb target genes in intestinal cancer is mediated by inflammation, Cancer Res. 68, 10280-10289.
 
Rauch, T.A., Wu, X., Zhong, X., Riggs, A.D., and Pfeifer, G.P. (2009) A human B cell methylome at 100 bp resolution, Proc. Natl. Acad. Sci. USA 106, 671-678.
 
Wu, X., Rauch, T.A., Zhong, X., Bennett, W.P., Latif, F., Krex, D., and Pfeifer, G.P. (2010) CpG island hypermethylation in human astrocytomas, Cancer Res. 70, 2718-2727.
 
Kalari, S., Jung, M., Kernstine, K.H., Takahashi, T., and Pfeifer, G.P. (2013) The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells, Oncogene 32, 3559-3568.
 
 

Mammalian neurogenesis

Mammalian neurogenesis

In collaboration with Dr. Qiang Lu, City of Hope, we are investigating changes in DNA cytosine modification and histone modifications in the developing mouse brain. The focus is on how these epigenetic events orchestrate gene expression patterns during neurogenesis (Hahn et al., 2013).
 
Hahn, M.A., Qiu, R., Wu, X., Li, A.X., Wang, J., Zhang, H., Jui, J., Jin, S.G., Jiang, Y., Pfeifer, G.P.,* and Lu, Q.* (2013) Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis, Cell Reports 3, 291-300.
 
 

RASSF1 and the Hippo pathway

RASSF1 and the Hippo pathway

The biological significance of aberrant methylation in cancer (“driver” versus “passenger” methylation) is unclear (Kalari et al., 2010). Earlier, we identified and characterized the gene RASSF1A (Dammann et al., 2000). This gene undergoes methylation silencing in almost every type of human tumor (~1000 publications in PubMed). In the face of increasing numbers of cancer genome sequencing studies identifying mutations in critical genes, researchers are loosing sight of the breadth and significance of cancer-associated promoter hypermethylation. The RASSF1A pathway is a prime example highlighting the importance of epigenetic silencing events in tumors in the absence of frequent mutation of a gene. We identified RASSF1A as an upstream regulator of the Hippo tumor suppressor pathway (Guo et al., 2007). Interestingly, the one component of the Hippo pathway most frequently affected in human cancer is RASSF1A, which is silenced by promoter methylation in over 90% of human liver tumors, for example. Therefore, this promoter methylation is of high significance and we continue to study the biochemical function of RASSF1A and its related family members in the mammalian Hippo pathway and other tumor-relevant processes.
 
Dammann, R., Li, C., Yoon, J.-H., Chin, P.L., Bates, S., and Pfeifer, G.P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nature Genet. 25, 315-319.
 
Guo, C., Tommasi, S., Liu, L., Yee, J.-K., Dammann, R., and Pfeifer, G.P. (2007) The RASSF1A tumor suppressor protein is a component of a mammalian complex analogous to the Drosophila Hippo/Salvador/Lats tumor suppressor network, Curr. Biol. 17, 700-705.
 
Kalari, S., and Pfeifer, G.P. (2010) Identification of driver and passenger DNA methylation in cancer by epigenomic analysis, Adv. Genet. 70, 277-308.
 
Pfeifer, G.P., Dammann, R., and Tommasi, S. (2010) RASSF proteins, Curr. Biol. 20, R344-R345.
 

 
 

UV damage and repair

UV damage and repair

Exposure to ultraviolet (UV) causes melanoma and non-melanoma skin cancer in humans and UV-specific mutation patterns can be found in tumor genomes (Pfeifer and Hainaut, 2011). This work is an ongoing project supporting studies on UV-induced DNA damage, repair and mutagenesis. Part of the current work is aimed at investigating mechanisms of epigenetic changes induced by different types of UV radiation (Lahtz et al., 2013). One main goal is to obtain high-resolution DNA damage maps of UV-induced cyclobutane pyrimidine dimers (CPDs), the main DNA lesion induced by UVB radiation. We are currently developing methodology for base-resolution mapping of CPDs thus allowing a precise assessment of genomic UV damage and its relationship to features of DNA sequence and chromatin. Another goal is to study epigenetic changes in melanoma and relate them to genetic changes in the same tumors.
 
Pfeifer, G.P. and Hainaut, P., (2011) Next generation sequencing: emerging lessons on the origins of human cancer, Curr. Opin. Oncol. 23, 62–68.
 
Lahtz, C., Kim, S.I., Bates, S.E., Li, A.X., Wu, X., and Pfeifer, G.P. (2013) UVB irradiation does not directly induce detectable changes of DNA methylation in human keratinocytes, F1000Research, v1, online Feb 13, 2013. http://f1000r.es/np.

 
 

Lab Members

Gerd Pfeifer, Ph.D. Lab Members

 
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Patients at City of Hope – most of whom are fighting cancer – rely on more than 37,000 units of blood and platelets each year for their treatment and survival. Every one of those units comes from family, friends or someone who traded an hour or so of their time and a pint of their […]
  • Surgery is vital in the treatment of cancer – it’s used to help diagnose, treat and even prevent the disease – so a new colorectal cancer study linking a decrease in surgeries for advanced cancer to increased survival rates may raise more questions than it answers for some patients. The surgery-and-surviv...
  • Age is the single greatest risk factor overall for cancer; our chances of developing the disease rise steeply after age 50. For geriatric oncology nurse Peggy Burhenn, the meaning is clear: Cancer is primarily a geriatric condition. That’s why she is forging inroads in the care of older adults with cancer. Burh...
  • One of American’s great sportscasters, Stuart Scott, passed away from recurrent cancer of the appendix at the young age of 49. His cancer was diagnosed when he was only 40 years old. It was found during an operation for appendicitis. His courageous fight against this disease began in 2007, resumed again with an...
  • When Homa Sadat found a lump in her breast at age 27, her gynecologist told her what many doctors say to young women: You’re too young to have breast cancer. With the lump dismissed as a harmless cyst, she didn’t think about it again until she was at a restaurant six months later and felt […]
  • What most people call a “bone marrow transplant” is not actually a transplant of bone marrow; it is instead the transplantation of what’s known as hematopoietic stem cells. Such cells are often taken from bone marrow, but not always. Hematopoietic stem cells are simply immature cells that can ...
  • Doctors have long known that women with a precancerous condition called atypical hyperplasia have an elevated risk of breast cancer. Now a new study has found that the risk is more serious than previously thought. Hyperplasia itself is an overgrowth of cells; atypical hyperplasia is an overgrowth in a distorted...
  • Don’t kid yourself. Just because it’s mid-January doesn’t mean it’s too late to make resolutions for a happier, and healthier, 2015. Just consider them resolutions that are more mature than those giddy, sometimes self-deluded, Jan. 1 resolutions. To that end, we share some advice from Cary A. Presant, M.D., an ...
  • Sales and marketing executive Jim Murphy first came to City of Hope in 2002 to donate blood for a friend who was being treated for esophageal cancer. The disease is serious. Although esophageal cancer accounts for only about 1 percent of cancer diagnoses in the U.S., only about 20 percent of patients survive at...
  • Aaron Bomar and his family were celebrating his daughter’s 33rd birthday in September 2014 when he received alarming news: According to an X-ray taken earlier that day at an urgent care facility, he had a node on his aorta and was in danger of an aneurysm. Bomar held hands with his wife and daughter and s...
  • Explaining a prostate cancer diagnosis to a young child can be difficult — especially when the cancer is incurable. But conveying the need for prostate cancer research, as it turns out, is easily done. And that leads to action. Earlier this year, Gerald Rustad, 71, who is living with a very aggressive form of m...
  • Cancer and its treatment can create unexpected daily challenges for patients. Side effects from chemotherapy, surgery and radiation therapy as well as the disease itself can cause difficulty in everything from speech to movement to eating. When this happens, rehabilitation is vital; it helps patients restore th...
  • Betsy Sauer and her four daughters share plenty in common. They’re smart and successful.  They’re funny, ranging from wryly witty to wickedly hilarious. Their hobbies tend toward the active and adventurous: hiking, rock climbing, skiing, swimming, fishing, kayaking, yoga and horseback riding. Also, they take he...
  • Flu season is upon us, and few people should take the risk of infection more seriously than cancer patients and their loved ones and caregivers. With the federal Centers for Disease Control and Prevention warning of widespread influenza outbreaks, it’s clear that flu season – and the associated risks – won’t en...
  • HIV/AIDS researchers are determined not only to cure the disease, but to develop ever-more-effective treatments until that ultimate goal is reached. In 2015, they will gain ground in both endeavors. In search of a cure: Stem cell and gene therapy One of the most promising prospects for curing HIV is to recreate...